INTRAPERITONEAL RADIOIMMUNOTHERAPY OF OVARIAN-CANCER WITH LUTETIUM-177-CC49

Twelve ovarian cancer patients who failed chemotherapy entered a Phase I trial of intraperitoneal Lu-177-CC49 antibody. Methods: Patients ha d disease confined to the abdominal cavity +/- retroperitoneal lymph n odes, adequate organ function and no previous radiation. Results: Side effects included mild discomfort with administration (1/12), delayed transient arthralgia (2/12), and mild marrow suppression (calculated m arrow doses of 11-54 cGy). The maximum tolerated dose has not been rea ched with levels of 10, 18, 25 and 30 mCi/m(2). Radioimmunoscintigraph y revealed localization consistent with tumor in 11 of 12 patients. On e of eight patients with gross disease had > 50% tumor reduction after therapy, while six progressed and one went off study with stable dise ase. Of patients with microscopic or occult disease, one relapsed at 1 0 mo and three remain without evidence of disease after 18 mo. Conclus ion: Intraperitoneal radioimmunotherapy with Lu-177-CC49 is well toler ated and appears to have antitumor activity against chemotherapy-resis tant ovarian cancer in the peritoneal cavity.